Mary Reumuth Sells 4,163 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 4,163 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total value of $19,774.25. Following the sale, the chief financial officer now directly owns 60,187 shares in the company, valued at approximately $285,888.25. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Mary Reumuth also recently made the following trade(s):

• On Friday, May 31st, Mary Reumuth sold 1,786 shares of KALA BIO stock. The stock was sold at an average price of $6.09, for a total value of $10,876.74.

KALA BIO Price Performance

KALA stock opened at $7.09 on Friday. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $16.11. The company has a debt-to-equity ratio of 4.92, a quick ratio of 4.22 and a current ratio of 4.22. The stock’s 50 day moving average price is $6.39 and its 200 day moving average price is $7.02. The firm has a market cap of $19.99 million, a P/E ratio of -0.47 and a beta of -1.97.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, May 14th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.89) by ($1.31). On average, sell-side analysts expect that KALA BIO, Inc. will post -14.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on KALA shares. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research note on Monday, April 1st. HC Wainwright decreased their price target on KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, May 17th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.